Device manufacturer Medtronic announced the first patient was implanted in its evaluation of InterStim Micro system performance and safety (ELITE) study.
In the ELITE study, researchers investigated the use of a rechargeable sacral neurostimulation system, InterStim Micro, to help with symptoms of overactive bladder, including urinary urge incontinence, urinary frequency, nonobstructive urinary retention, and fecal incontinence.
ELITE will enroll 160 patients across 40 sites in the U.S., Europe, Australia, and Canada. Patients will be followed for two years and will report outcomes, fill out disease-specific quality of life questionnaires, and symptom diaries.
InterStim Micro features Medtronic's SureScan MRI technology, which does not require impedance checks prior to an MRI scan.
